Indaptus Therapeutics Stock Today

INDP Stock  USD 2.30  0.01  0.43%   

Performance

8 of 100

 
Weak
 
Strong
OK

Odds Of Distress

Less than 21

 
High
 
Low
Low
Indaptus Therapeutics is selling at 2.30 as of the 21st of May 2024; that is -0.43 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 2.3. Indaptus Therapeutics has about a 21 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Indaptus Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 21st of April 2024 and ending today, the 21st of May 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
4th of August 2015
Category
Healthcare
Classification
Health Care
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York. Indaptus Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 8.54 M outstanding shares of which 25.81 K shares are currently shorted by private and institutional investors with about 2.06 trading days to cover. More on Indaptus Therapeutics

Moving against Indaptus Stock

  0.64LFCR Lifecore Biomedical Financial Report 6th of June 2024 PairCorr
  0.62MREO Mereo BioPharma Group Earnings Call This WeekPairCorr
  0.61IRWD Ironwood PharmaceuticalsPairCorr
  0.56RDY Dr Reddys LaboratoriesPairCorr
  0.55INCY IncytePairCorr
  0.5JNJ Johnson Johnson Financial Report 18th of July 2024 PairCorr
  0.44LSDI Lucy Scientific DiscoveryPairCorr

Indaptus Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Indaptus Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Indaptus Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary, Indaptus Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Indaptus Therapeutics' managers, analysts, and investors.
Environmental
Governance
Social
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Analysts covering Indaptus Therapeutics report their recommendations after researching Indaptus Therapeutics' financial statements, talking to executives and customers, or listening in on Indaptus Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Indaptus Therapeutics. The Indaptus consensus assessment is calculated by taking the average forecast from all of the analysts covering Indaptus Therapeutics.
Financial Strength
Based on the key indicators related to Indaptus Therapeutics' liquidity, profitability, solvency, and operating efficiency, Indaptus Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in June. Financial strength of Indaptus Therapeutics is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
Current ValueLast YearChange From Last Year 10 Year Trend
Total Current Liabilities3.4 M2.8 M
Fairly Up
Slightly volatile
Non Current Liabilities Total69.7 K73.3 K
Notably Down
Slightly volatile
Total Assets23.5 M14.9 M
Way Up
Very volatile
Total Current Assets21.4 M14 M
Way Up
Slightly volatile
Indaptus Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Indaptus Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Indaptus Therapeutics' financial leverage. It provides some insight into what part of Indaptus Therapeutics' total assets is financed by creditors.
By using current balance sheet information, investors can analyze the liability, assets, and equity on Indaptus Therapeutics' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Indaptus Therapeutics deploys its capital and how much of that capital is borrowed.
Liquidity
Indaptus Therapeutics cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 175.05 K in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. Indaptus Therapeutics has a current ratio of 9.0, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Indaptus Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Indaptus Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Indaptus Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Indaptus to invest in growth at high rates of return. When we think about Indaptus Therapeutics' use of debt, we should always consider it together with cash and equity.

Other Cashflows From Financing Activities

10 Million
Indaptus Therapeutics (INDP) is traded on NASDAQ Exchange in USA. It is located in Three Columbus Circle, New York, NY, United States, 10019 and employs 7 people. Indaptus Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 19.64 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Indaptus Therapeutics's market, we take the total number of its shares issued and multiply it by Indaptus Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Indaptus Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 8.54 M outstanding shares of which 25.81 K shares are currently shorted by private and institutional investors with about 2.06 trading days to cover. Indaptus Therapeutics currently holds about 33.01 M in cash with (13.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.0, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Indaptus Therapeutics Probability Of Bankruptcy
Ownership Allocation
Indaptus Therapeutics secures a total of 8.54 Million outstanding shares. Indaptus Therapeutics secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Indaptus Ownership Details

Indaptus Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Indaptus Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Indaptus Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Indaptus Therapeutics' value.
InstituionRecorded OnShares
Bangor Savings Bank2024-03-31
400
Wells Fargo & Co2023-12-31
104
Royal Bank Of Canada2023-12-31
38.0
Jpmorgan Chase & Co2023-12-31
9.0
Group One Trading, Lp2023-12-31
7.0
Bank Of America Corp2023-12-31
3.0
Qube Research & Technologies2023-12-31
1.0
Northern Trust Corp2023-09-30
0.0
Vanguard Group Inc2023-12-31
256.3 K
Investment House Llc2023-12-31
102.4 K
Geode Capital Management, Llc2023-12-31
54.8 K
View Indaptus Therapeutics Diagnostics

Indaptus Therapeutics Historical Income Statement

Indaptus Therapeutics Income Statement is one of the three primary financial statements used for reporting Indaptus's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Indaptus Therapeutics revenue and expense. Indaptus Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Indaptus Therapeutics' Interest Expense is relatively stable compared to the past year. As of 05/21/2024, Total Other Income Expense Net is likely to grow to about 1 M, while Gross Profit is likely to drop (1.3 K). View More Fundamentals

Indaptus Stock Against Markets

Picking the right benchmark for Indaptus Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Indaptus Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Indaptus Therapeutics is critical whether you are bullish or bearish towards Indaptus Therapeutics at a given time. Please also check how Indaptus Therapeutics' historical prices are related to one of the top price index indicators.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Indaptus Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Fundamentals Comparison Now

   

Fundamentals Comparison

Compare fundamentals across multiple equities to find investing opportunities
All  Next Launch Module

Indaptus Therapeutics Corporate Management

Elected by the shareholders, the Indaptus Therapeutics' board of directors comprises two types of representatives: Indaptus Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Indaptus. The board's role is to monitor Indaptus Therapeutics' management team and ensure that shareholders' interests are well served. Indaptus Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Indaptus Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
MD MBAChief OfficerProfile
Jeffrey MecklerCEO DirectorProfile
Walt EsqChief OfficerProfile
Michael NewmanChief FounderProfile
Boyan MDChief OfficerProfile

How to buy Indaptus Stock?

Before investing in Indaptus Therapeutics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Indaptus Therapeutics. To buy Indaptus Therapeutics stock, you can follow these steps:
  • Choose a brokerage firm: You need to select a brokerage firm to buy shares of Indaptus Therapeutics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
  • Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
  • Fund your account: You will need to deposit funds into your brokerage account to purchase Indaptus Therapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
  • Place your order: Once you have located Indaptus Therapeutics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
  • Monitor your investment: After you have purchased Indaptus Therapeutics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Indaptus Therapeutics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Indaptus Stock please use our How to Invest in Indaptus Therapeutics guide.

Already Invested in Indaptus Therapeutics?

The danger of trading Indaptus Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Indaptus Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Indaptus Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Indaptus Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Indaptus Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Indaptus Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Indaptus Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Indaptus Therapeutics Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Indaptus Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.
To learn how to invest in Indaptus Stock, please use our How to Invest in Indaptus Therapeutics guide.
Note that the Indaptus Therapeutics information on this page should be used as a complementary analysis to other Indaptus Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Complementary Tools for Indaptus Stock analysis

When running Indaptus Therapeutics' price analysis, check to measure Indaptus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Indaptus Therapeutics is operating at the current time. Most of Indaptus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Indaptus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Indaptus Therapeutics' price. Additionally, you may evaluate how the addition of Indaptus Therapeutics to your portfolios can decrease your overall portfolio volatility.
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Fundamental Analysis
View fundamental data based on most recent published financial statements
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Is Indaptus Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Indaptus Therapeutics. If investors know Indaptus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Indaptus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.83)
Return On Assets
(0.48)
Return On Equity
(0.84)
The market value of Indaptus Therapeutics is measured differently than its book value, which is the value of Indaptus that is recorded on the company's balance sheet. Investors also form their own opinion of Indaptus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Indaptus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Indaptus Therapeutics' market value can be influenced by many factors that don't directly affect Indaptus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Indaptus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Indaptus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Indaptus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.